Phase 2 N=110 Safety Evaluation of 3K3A-APC in Ischemic Stroke
Ischemic Stroke
Primary: Number of Participants With Adverse Events That Meet Dose-limiting Toxicity (DLT) Criteria Specified in Protocol — 0; 1; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=875 Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine
Migraine
Primary: Change From Baseline in the Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Study Drug — -2.7; -4.0; -4.2 days — p=<0.0001
Phase 3 N=7,180 Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis
Postmenopausal Osteoporosis
Primary: Percentage of Participants With New Vertebral Fracture Through Month 12 — 1.8; 0.5 percentage of participants — p=< 0.001
Phase 3 N=756 Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease
Anemia in Chronic Kidney Disease Patients Not on Dialysis
Primary: Percentage of Participants in Receipt of 1 or More RBC Transfusions — 24.40; 24.14 Percentage of Participants
N/A N=160 Efficacy of Intrauterine Lidocaine and Naproxen for Pain Control With Intrauterine Device Insertion
Contraception · Pain
Primary: Pain Control With IUD Insertion — 3.606; 3.088; 2.83; 3.382 units on a scale
Phase 1 N=43 Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma
Multiple Myeloma
Primary: Cmax: Maximum Observed Plasma Concentration for Ixazomib — 37.57 ng/mL
Phase 4 N=159 IV Acetaminophen as an Analgesic Adjunct
Acute Pain
Primary: Change in Pain Intensity, Baseline to 60 Minutes After Medication Infused — 5.8; 5.2 units on a scale
N/A N=314 Spaeth/Richman Contrast Sensitivity Test
Glaucoma
Primary: Contrast Sensitivity, Another Means of Testing Vision — 59.4; 74.4; 53.9 units on a scale
Phase 1 N=54 Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects
Asthma (Part 1) · COPD (Part 2)
Primary: The Number of Participants With Mild Persistent Asthma (Part 1) and COPD (Part 2) With at Least 1 Treatment-emergent Adverse Event — 5; 5; 3; 3 Participants
Phase 4 N=51 A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia
Schizophrenia
Primary: Change From Baseline to Last Treatment Visit in Clinical Global Impressions-Severity (CGI-S) Scores — -0.2 units on a scale — p=0.078
N/A N=144 Home Exercise to Enhance Mobility for Older Diabetics
Diabetes Mellitus Type 2
Primary: Comfortable Gait Speed — 1.2; 1.2 meters per second — p=0.16
Phase 3 N=294 A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis
Postmenopausal Osteoporosis
Primary: Percent Change From Baseline in Bone Mineral Density (BMD) at the Lumbar Spine — 0.8; 9.6; 9.2 percent change
Phase 4 N=42 Endogenous Opioid Activity and Affective State in Insulin Resistant Women
Depression · Insulin Resistance · Metabolic Syndrome
Primary: Mu-opioid Receptor Binding Potential in Left Nucleus Accumbens, Resting State
Phase 3 N=436 An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women
Postmenopausal Osteoporosis
Primary: Percent Change From Baseline Through Month 12 in Total Hip Bone Mineral Density (BMD) — -0.6; 2.6 percent change — p=< 0.0001
N/A N=3,317 Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With α-GI"
Type 2 Diabetes Mellitus Who Have Been Examined at a Medical Institution
Primary: Number of Participants Who Experience at Least One Adverse Events — 151; 98; 139 Participants